International Medical Center of Biomaterials Processing and Cryostorage (MOEX: GEMA)
Russia
· Delayed Price · Currency is RUB 672.00
-1.50 (-0.22%)
At close: Jul 8, 2022
MOEX: GEMA Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 326.74 | 283.51 | 254.68 | 265.89 | 242.63 | 238.59 | Upgrade
|
| Revenue Growth (YoY) | 18.56% | 11.32% | -4.22% | 9.59% | 1.69% | -1.67% | Upgrade
|
| Cost of Revenue | 54.01 | 47.95 | 51.67 | 61.82 | 30.87 | 18.89 | Upgrade
|
| Gross Profit | 272.72 | 235.56 | 203 | 204.07 | 211.76 | 219.7 | Upgrade
|
| Selling, General & Admin | 105.44 | 86.2 | 64.41 | 65.52 | 53.69 | 69.24 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 5.81 | 7.72 | Upgrade
|
| Operating Expenses | 105.44 | 86.2 | 64.41 | 66.17 | 69.9 | 82.28 | Upgrade
|
| Operating Income | 167.28 | 149.36 | 138.6 | 137.9 | 141.86 | 137.43 | Upgrade
|
| Interest Expense | -34.24 | -33.56 | -17.62 | -3.52 | -6.84 | -4.68 | Upgrade
|
| Interest & Investment Income | 5.43 | 11.98 | 10.54 | 17.48 | 2.24 | 5.23 | Upgrade
|
| Earnings From Equity Investments | 9 | 6.53 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | -0.09 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -15.64 | -8.73 | -32 | -18.7 | -14.39 | -18.71 | Upgrade
|
| EBT Excluding Unusual Items | 131.83 | 125.58 | 99.52 | 133.17 | 122.77 | 119.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.2 | 0.2 | -1.35 | -4 | - | - | Upgrade
|
| Pretax Income | 132.03 | 125.78 | 98.17 | 129.17 | 122.77 | 119.26 | Upgrade
|
| Net Income | 132.03 | 125.78 | 98.17 | 129.17 | 122.77 | 119.26 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | -21.57 | - | - | Upgrade
|
| Net Income to Common | 132.03 | 125.78 | 98.17 | 150.74 | 122.77 | 119.26 | Upgrade
|
| Net Income Growth | 1.22% | 28.13% | -24.00% | 5.21% | 2.95% | -15.88% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 13 | Upgrade
|
| Shares Change (YoY) | - | - | -0.00% | 0.00% | 11.11% | 5.88% | Upgrade
|
| EPS (Basic) | 8.84 | 8.42 | 6.58 | 10.10 | 8.22 | 8.88 | Upgrade
|
| EPS (Diluted) | 8.84 | 8.42 | 6.58 | 10.10 | 8.22 | 8.88 | Upgrade
|
| EPS Growth | 1.22% | 28.13% | -34.88% | 22.79% | -7.35% | -20.55% | Upgrade
|
| Free Cash Flow | - | 209.59 | 231.83 | 239.82 | 132.26 | 113.14 | Upgrade
|
| Free Cash Flow Per Share | - | 14.04 | 15.53 | 16.06 | 8.86 | 8.42 | Upgrade
|
| Dividend Per Share | 7.920 | 6.420 | 8.022 | 8.650 | - | - | Upgrade
|
| Dividend Growth | -11.23% | -19.97% | -7.26% | - | - | - | Upgrade
|
| Gross Margin | 83.47% | 83.09% | 79.71% | 76.75% | 87.28% | 92.08% | Upgrade
|
| Operating Margin | 51.20% | 52.68% | 54.42% | 51.86% | 58.47% | 57.60% | Upgrade
|
| Profit Margin | 40.41% | 44.36% | 38.55% | 56.69% | 50.60% | 49.98% | Upgrade
|
| Free Cash Flow Margin | - | 73.93% | 91.03% | 90.20% | 54.51% | 47.42% | Upgrade
|
| EBITDA | 178.91 | 157.64 | 142.41 | 142.04 | 148.31 | 141.02 | Upgrade
|
| EBITDA Margin | 54.76% | 55.60% | 55.92% | 53.42% | 61.13% | 59.10% | Upgrade
|
| D&A For EBITDA | 11.63 | 8.28 | 3.81 | 4.15 | 6.45 | 3.59 | Upgrade
|
| EBIT | 167.28 | 149.36 | 138.6 | 137.9 | 141.86 | 137.43 | Upgrade
|
| EBIT Margin | 51.20% | 52.68% | 54.42% | 51.86% | 58.47% | 57.60% | Upgrade
|
| Revenue as Reported | - | - | - | - | 242.63 | 238.59 | Upgrade
|
| Advertising Expenses | - | 23.97 | 17.11 | 15.86 | 8.17 | 10.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.